Use access key #2 to skip to page content.

gup (< 20)

No Lucky Charms earned yet.

Is it a good time to buy Gale



February 01, 2014 – Comments (7) | RELATED TICKERS: GALE

Gale biopharma has many breast cancer drugs in their pipeline. Nuevax is the most promising one at this time. It is in phase 3 trial. But many drugs in their pipeline are also in clinical trials. Is it a good time to start a position in this company?

7 Comments – Post Your Own

#1) On February 01, 2014 at 7:30 AM, GirlsUnder30 (30.63) wrote:

If you're looking for a healthcare play you should read: 

Report this comment
#2) On February 01, 2014 at 9:51 AM, HarryCaraysGhost (86.66) wrote:

I would defer to this guy when it comes to biotech-

zzlangerhans (99.76) Submitted: 12/2/2013 3:33:51 AM : Start Price: $3.90 GALE Score: -36.53

I finally let go of my Galena outperform a few weeks ago after it had stagnated in the low 2's for months. The stock rewarded me by promptly embarking on a sharp upward tear that would have provided me another 150 CAPS points. What suddenly blasted the stock out of its recent trading range? I have no idea. There's never been any shortage of fawning SA articles, and the ones published around the time of the breakout don't seem particularly original or inspired. The recent earnings CC didn't seem to provide any surprising or positive information either. The PRESENT trial continues to enroll without an estimated time of completion, although Zacks has predicted enrollment would be complete before the end of 2013. Abstral is unlikely to be a game changer for Galena, and the cheaply acquired pain drug wasn't even launched until October. I even considered the possibility of an uncorking effect from the damage done to Feuerstein, the stock's greatest critic, by his surprising double faceplant on Vanda and Sarepta. However, it seems clear that the move in Galena began at least 10 days before Feuerstein's bad day. So like many a move in small cap biopharma stocks, this one will remain a mystery to me. Nevertheless, I'll go with my long-term view on the prospects of PRESENT and drop a red thumb for the eventual trial failure.  

Report this comment
#3) On February 01, 2014 at 12:07 PM, Teacherman1 (< 20) wrote:

gup, if you are new to trading and not just new to the Motley Fool, you might want to stay away from the small biopharms. They are among the most volatile around.

They can pay off big when it works out, but they can also kill you along the way.

As Harry mentioned above,  zzlangerhans "specializes" in this area, so you might look to see what they have to say, if anything.

Again, welcome to CAPS and good luck.       


Report this comment
#4) On February 01, 2014 at 11:37 PM, Mary953 (85.34) wrote:


I am so glad you posted your first blog.  I am a disaster with biopharma, but zz and porte have sent me in the right direction and helped me make money in the sector.  Like GirlsUnder30, I made some money on POZN and I am rooting for them to do well.  My best advice is to figure out what you really understand and then look at the companies there for investment opportunities.  Invest in what you know.

Here is your link to the new welcome index of blogs.  This way, since I hope you have marked the following tab on your own blog, you will be able to scroll back to your first blog and find the index if you want it.  The link is

+1 for the joy of having you here as an active blogger!


Report this comment
#5) On February 04, 2014 at 5:36 PM, jiltin (44.99) wrote:


Thanks for pointing out zzlangerhans "specializes" in this area. I have added in my favorites.  Who else tracking such small caps or small sectors? 

Report this comment
#6) On February 04, 2014 at 10:05 PM, HarryCaraysGhost (86.66) wrote:

I was hoping porte would post a new post-

Stick with these guys if your into biotech.

Personally I wouldn't touch them, but that's just me.


Report this comment
#7) On February 05, 2014 at 12:36 AM, jiltin (44.99) wrote:

Harry, thank you

Report this comment

Blog Archive

February (1)

Featured Broker Partners